• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.

作者信息

Otoukesh Salman, Salhotra Amandeep, Marcucci Guido, Forman Stephen J, Pullarkat Vinod, Aldoss Ibrahim

机构信息

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, United States.

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, United States.

出版信息

Leuk Res. 2019 Sep;84:106196. doi: 10.1016/j.leukres.2019.106196. Epub 2019 Jul 30.

DOI:10.1016/j.leukres.2019.106196
PMID:31377457
Abstract
摘要

相似文献

1
The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.维奈托克和地西他滨用于治疗相关急性髓系白血病合并晚期非血液系统恶性肿瘤的可行性。
Leuk Res. 2019 Sep;84:106196. doi: 10.1016/j.leukres.2019.106196. Epub 2019 Jul 30.
2
Venetoclax with decitabine or azacitidine for AML.维奈托克联合地西他滨或阿扎胞苷治疗急性髓系白血病
Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.
3
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.维奈克拉与去甲基化药物联合治疗复发/难治性急性髓系白血病的疗效
Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15.
4
Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.维奈托克与低甲基化药物联合治疗骨髓增殖性肿瘤继发的急性髓系白血病
Leuk Res. 2020 Nov;98:106456. doi: 10.1016/j.leukres.2020.106456. Epub 2020 Sep 22.
5
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).接受去甲基化药物联合维奈克拉（HMA-Ven）或脂质体柔红霉素-阿糖胞苷（CPX-351）治疗的继发性急性髓系白血病的治疗结果
Am J Hematol. 2021 Jun 1;96(6):E196-E200. doi: 10.1002/ajh.26157. Epub 2021 Apr 8.
6
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.地西他滨和维奈克拉治疗异柠檬酸脱氢酶1/2突变的急性髓系白血病
Am J Hematol. 2021 May 1;96(5):E154-E157. doi: 10.1002/ajh.26122. Epub 2021 Feb 19.
7
Hypomethylating agents and venetoclax in acute myeloid leukemia.急性髓系白血病中的去甲基化药物与维奈克拉
Clin Adv Hematol Oncol. 2021 Feb;19(2):82-83.
8
Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.维奈托克联合地西他滨可诱导造血干细胞移植后复发的急性髓系白血病完全缓解并伴有分子学反应。
Am J Hematol. 2019 Feb;94(2):E48-E50. doi: 10.1002/ajh.25352. Epub 2018 Nov 29.
9
Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.维奈托克联合低甲基化药物治疗低危急性髓系白血病的疗效
Am J Hematol. 2021 Mar 1;96(3):E59-E63. doi: 10.1002/ajh.26057. Epub 2020 Dec 8.
10
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.

引用本文的文献

1
How I treat secondary acute myeloid leukemia.我如何治疗继发性急性髓系白血病。
Blood. 2025 Mar 20;145(12):1260-1272. doi: 10.1182/blood.2024024011.
2
Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.嵌合抗原受体 T 细胞（CAR T）治疗难治/复发 B 细胞淋巴瘤后发生的继发性髓系肿瘤：病例系列及文献复习。
Front Immunol. 2023 Jan 13;13:1063986. doi: 10.3389/fimmu.2022.1063986. eCollection 2022.
3
Active DNA demethylation-The epigenetic gatekeeper of development, immunity, and cancer.
活性DNA去甲基化——发育、免疫和癌症的表观遗传守门人。
Adv Genet (Hoboken). 2020 Nov 27;2(1):e10033. doi: 10.1002/ggn2.10033. eCollection 2021 Mar.
4
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies.安全性与疗效：维奈克拉联合去甲基化药物治疗新诊断及复发/难治性晚期髓系恶性肿瘤的临床经验
Hemasphere. 2021 Mar 9;5(4):e549. doi: 10.1097/HS9.0000000000000549. eCollection 2021 Apr.